Director of Research Center
Montreal Heart Institute
Montreal, Quebec, Canada
Dr. Jean-Claude Tardif is the Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at UofM. He holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC).
His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as early clinical studies and large international randomized trials. Dr Tardif is or has been the international principal investigator or part of the study leadership of several large trials in the field of atherosclerosis and other CV diseases.
Dr Tardif has authored >800 scientific articles and was inducted in the Order of Canada (the highest distinction in the country).
Disclosure(s): Boehringer Ingelheim Pharmaceutical, Inc.: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Ongoing); DalCor Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Grant/Research Support (Ongoing); Pfizer,: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)
What is new with Dalcetrapib? | Why it is Different from the Other CETP Inhibitors?
Sunday, March 9, 2025
11:15 AM – 11:23 AM ET
Panel Discussion | Atherosclerosis Therapeutic Options and Management - What is Promising?
Sunday, March 9, 2025
12:03 PM – 12:15 PM ET